CSTL
Castle Biosciences IncKey Statistics
About Castle Biosciences Inc
Castle Biosciences Inc. is a pioneering diagnostics firm that focuses on advancing patient care through innovative gene-expression profiling tests, primarily targeting skin cancer. Its flagship product, DecisionDx®-Melanoma, plays a crucial role in melanoma management by offering essential insights for patient risk stratification and informed treatment decisions. Committed to precision medicine, Castle is enhancing its product portfolio to meet significant clinical needs and has established a strong research and development foundation to drive future growth. With a strategic emphasis on addressing the complexities of the oncology landscape, the company is well-positioned to improve clinical outcomes while delivering substantial shareholder value.
Fundamentals
| Revenue (TTM) | $339.92M |
| Gross Profit (TTM) | $264.74M |
| EBITDA | $-18.35M |
| Operating Margin | -22.00% |
| Return on Equity | -2.85% |
| Return on Assets | -3.97% |
| Revenue/Share (TTM) | $11.60 |
| Book Value | $15.23 |
| Price-to-Book | 1.32 |
| Price-to-Sales (TTM) | 1.80 |
| EV/Revenue | 1.134 |
| EV/EBITDA | 42.95 |
| Quarterly Earnings Growth (YoY) | -51.60% |
| Quarterly Revenue Growth (YoY) | -4.90% |
| Shares Outstanding | $30.33M |
| Float | $26.87M |
| % Insiders | 2.38% |
| % Institutions | 92.97% |
Historical Volatility
Volatility is currently contracting